Who should be vaccinated?

Meningococcal meningitis may be rare—with only 1,200-3,500 cases yearly in the US1—but 1 in 10 people who contract the disease die from it, even with appropriate treatment.2 And while anyone can get meningococcal disease, adolescents and young adults are among those at increased risk.  They account for nearly 30% of all US cases, yet it is estimated that the majority of these cases could be prevented with a vaccination.2,3

CDC recommendations for vaccination

Recognizing the risks, the Centers for Disease Control and Prevention (CDC) has updated its recommendations to include vaccination for meningococcal disease for all children 11 through 18 years of age4:

  • Preteens at their 11- or 12-year-old checkup
  • Teens up to 18 years old as soon as possible if they haven’t been vaccinated

The CDC also recommends vaccinating certain high-risk groups, adults, and younger children including4:

  • College freshmen in dormitories
  • Recruits in the military
  • Travelers or residents of countries where the disease is common

You can download CDC vaccination recommendations for meningococcal disease and other diseases:

Indication

Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons 11 to 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.

Important Safety Information

You should not receive Menveo if you have had a severe allergic reaction to any ingredient of the vaccine, or if you have had a severe allergic reaction to a vaccine containing similar components as Menveo.

Side effects to Menveo include pain at the injection site, headache, muscle pain, fatigue, nausea, and fainting. Sometimes fainting is accompanied by falling with injury. Other side effects may occur.

Following vaccination with a US-licensed meningococcal conjugate vaccine, an evaluation of postmarketing adverse events suggested a potential for increased risk of Guillain-Barré Syndrome (GBS). There is not enough information to evaluate if a risk of GBS exists following administration of Menveo.

Tell your doctor if you are pregnant or planning to get pregnant.

Vaccination with Menveo may not protect all individuals.

For more information about Menveo, talk to your health-care professional.

Menveo.com has been developed by Novartis Vaccines as part of the company’s commitment to individual and public health.

References

  1. McNabb SJN, Jajosky RA, Hall-Baker PA, et al. Summary of notifiable diseases—United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;55:1–92.
  2. Meningococcal: Questions and answers. Immunization Action Coalition Web site. http://www.immunize.org/catg.d/p4210.pdf. Accessed March 3, 2010.
  3. Strunk JA, Rocchiccioli JT. Meningococcal meningitis: an emerging infectious disease. J Community Health Nurs. 2010;27:51–58.
  4. Meningitis: Meningococcal vaccination. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/meningitis/vaccine-info.html. Accessed March 3, 2010.
  5. State information: Meningococcal prevention mandates for colleges and universities. Immunization Action Coalition Web site. http://www.immunize.org/laws/menin.asp. Accessed March 3, 2010.
  6. State information: Meningococcal state mandates for elementary and secondary schools. Immunization Action Coalition Web site. http://www.immunize.org/laws/menin_sec.asp. Accessed March 3, 2010.

Menveo.com Exit Notice

You are now leaving the Menveo.com site and moving to an external website independently operated and not managed by Novartis Vaccines and Diagnostics Inc. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or, click OK to continue.

OKCancel